While preliminary, these findings encourage further research into the potential therapeutic benefits of this bioactive Bin1 MBD-targeting mAb to lower expression and deposition of phosphorylated tau, as a possible approach to treat AD and/or other tauopathies. The gene discussed is BIN1; the disease is tauopathy.